Linda Heimberg1, Stefan Knop1. 1. Medizinische Klinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Abstract
BACKGROUND: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients. SUMMARY: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibitor and an immunomodulatory drug, mostly lenalidomide. We focus on the treatment options for patients that are ineligible for (another) stem cell transplantation. We will review treatment options for relapse after first- or second-line therapy and beyond third-line. Key Messages: There is promising data supporting the efficacy and safety of triplet combinations containing anti-CD38-monoclonal antibodies (anti-CD38 mAbs) at first or second relapse in combination with next-generation compounds. For the treatment beyond third-line, comparative studies are scarce but some promising compounds are available via conditional authorization, and there is more to come in the future. We will present some early phase trials featuring promising results.
BACKGROUND: With the availability of T-cell-directed therapy and next-generation compounds of established classes of drugs, the treatment of relapsed/refractory (r/r) myeloma is getting more complex. However, treatment options in practice are limited by availability, approval, and patient comorbidity. The aim of this article is to provide a practical approach toward the choice of treatment for r/r myeloma patients. SUMMARY: Regarding market authorization and current guidelines, at least in Germany, most patients nowadays will have received a doublet or triplet combination as first-line therapy containing a proteasome inhibitor and an immunomodulatory drug, mostly lenalidomide. We focus on the treatment options for patients that are ineligible for (another) stem cell transplantation. We will review treatment options for relapse after first- or second-line therapy and beyond third-line. Key Messages: There is promising data supporting the efficacy and safety of triplet combinations containing anti-CD38-monoclonal antibodies (anti-CD38 mAbs) at first or second relapse in combination with next-generation compounds. For the treatment beyond third-line, comparative studies are scarce but some promising compounds are available via conditional authorization, and there is more to come in the future. We will present some early phase trials featuring promising results.
Authors: M A Dimopoulos; P Moreau; E Terpos; M V Mateos; S Zweegman; G Cook; M Delforge; R Hájek; F Schjesvold; M Cavo; H Goldschmidt; T Facon; H Einsele; M Boccadoro; J San-Miguel; P Sonneveld; U Mey Journal: Ann Oncol Date: 2021-02-03 Impact factor: 32.976
Authors: Sagar Lonial; Hans C Lee; Ashraf Badros; Suzanne Trudel; Ajay K Nooka; Ajai Chari; Al-Ola Abdallah; Natalie Callander; Nikoletta Lendvai; Douglas Sborov; Attaya Suvannasankha; Katja Weisel; Lionel Karlin; Edward Libby; Bertrand Arnulf; Thierry Facon; Cyrille Hulin; K Martin Kortüm; Paula Rodríguez-Otero; Saad Z Usmani; Parameswaran Hari; Rachid Baz; Hang Quach; Philippe Moreau; Peter M Voorhees; Ira Gupta; Axel Hoos; Eric Zhi; January Baron; Trisha Piontek; Eric Lewis; Roxanne C Jewell; Elisha J Dettman; Rakesh Popat; Simona Degli Esposti; Joanna Opalinska; Paul Richardson; Adam D Cohen Journal: Lancet Oncol Date: 2019-12-16 Impact factor: 41.316
Authors: Jens Hillengass; Saad Usmani; S Vincent Rajkumar; Brian G M Durie; María-Victoria Mateos; Sagar Lonial; Cristina Joao; Kenneth C Anderson; Ramón García-Sanz; Eloísa Riva; Juan Du; Niels van de Donk; Jesús G Berdeja; Evangelos Terpos; Elena Zamagni; Robert A Kyle; Jesús San Miguel; Hartmut Goldschmidt; Sergio Giralt; Shaji Kumar; Noopur Raje; Heinz Ludwig; Enrique Ocio; Rik Schots; Hermann Einsele; Fredrik Schjesvold; Wen-Ming Chen; Niels Abildgaard; Brea C Lipe; Dominik Dytfeld; Baldeep Mona Wirk; Matthew Drake; Michele Cavo; Juan José Lahuerta; Suzanne Lentzsch Journal: Lancet Oncol Date: 2019-06 Impact factor: 41.316
Authors: C C Bjorklund; L Lu; J Kang; P R Hagner; C G Havens; M Amatangelo; M Wang; Y Ren; S Couto; M Breider; Y Ning; A K Gandhi; T O Daniel; R Chopra; A Klippel; A G Thakurta Journal: Blood Cancer J Date: 2015-10-02 Impact factor: 11.037
Authors: Meletios Dimopoulos; Katja Weisel; Philippe Moreau; Larry D Anderson; Darrell White; Jesus San-Miguel; Pieter Sonneveld; Monika Engelhardt; Matthew Jenner; Alessandro Corso; Jan Dürig; Michel Pavic; Morten Salomo; Eva Casal; Shankar Srinivasan; Xin Yu; Tuong Vi Nguyen; Tsvetan Biyukov; Teresa Peluso; Paul Richardson Journal: Leukemia Date: 2020-09-07 Impact factor: 11.528
Authors: David S Siegel; Gary J Schiller; Kevin W Song; Richy Agajanian; Keith Stockerl-Goldstein; Hakan Kaya; Michael Sebag; Christy Samaras; Ehsan Malek; Giampaolo Talamo; Christopher S Seet; Jorge Mouro; William E Pierceall; Faiza Zafar; Weiyuan Chung; Shankar Srinivasan; Amit Agarwal; Nizar J Bahlis Journal: Br J Haematol Date: 2019-10-06 Impact factor: 6.998